['diabetic macular edema']
['ranibizumab 0.3 mg', 'aflibercept 2.0 mg']

        Inclusion Criteria:

          -  Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age > 21 years

          -  Exam and OCT confirming Diabetic Macular Edema

          -  Visual Acuity of 20/400 or better

          -  No history of post injection pain or inflammation in the past

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from this study

          -  History of Endophthalmitis in either eye

          -  Current inflammation in either eye

          -  Uncontrolled or symptomatic Dry Eye Syndrome

          -  Intravitreal injection less than 3 months ago

          -  History of Anterior or Posterior Uveitis

          -  History of post injection pain with prior treatments

          -  Recent thromboembolic event (<3 months)

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception.
      